Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin?

Authors

  • Gonçalo Cotovio Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal; Departamento de Psiquiatria e Saúde Mental, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal https://orcid.org/0000-0002-1267-645X
  • Ana Maia Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal; Departamento de Psiquiatria e Saúde Mental, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal https://orcid.org/0000-0003-2205-3368
  • Ana Velosa Departamento de Psiquiatria e Saúde Mental, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
  • Carolina Seybert Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal https://orcid.org/0000-0003-4028-5648
  • Albino J. Oliveira-Maia Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal; NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal https://orcid.org/0000-0001-5071-3007

DOI:

https://doi.org/10.51338/rppsm.2021.v7.i3.241

Keywords:

Depressive Disorder, Major/drug therapy, Hallucinogens/pharmacology, Psilocybin/pharmacology

Abstract

.

Downloads

Download data is not yet available.

References

Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Nichols DE. Psychedelics. Pharmacological reviews. 2016;68(2):264-355.

Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200-18.

Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. 2020;284:112749.

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry. 2020.

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 2021;384(15):1402-11.

Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell reports. 2018;23(11):3170-82.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences. 2012;109(6):2138-43.

Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports. 2017;7(1):1-11.

Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 2018;142:263-9.

Downloads

Published

2021-09-08

How to Cite

Cotovio, G., Maia, A., Velosa, A., Seybert, C., & Oliveira-Maia, A. J. (2021). Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin?. Revista Portuguesa De Psiquiatria E Saúde Mental, 7(3), 120–122. https://doi.org/10.51338/rppsm.2021.v7.i3.241

Issue

Vol. 7 No. 3 (2021)

Section

Perspective

Most read articles by the same author(s)